Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of S-1 alternate-day and bevacizumab in elderly patients with advanced colorectal cancer

Trial Profile

Phase II study of S-1 alternate-day and bevacizumab in elderly patients with advanced colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms J-SAVER
  • Most Recent Events

    • 09 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 20 Jan 2018 Primary endpoint (Progression-free survival) has been met, according to results presented at the 2018 Gastrointestinal Cancers Symposium.
    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top